Tigecycline: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== |
|||
*Glycylcycline antibiotic |
*Glycylcycline antibiotic |
||
== |
===Spectrum of Activity=== |
||
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
||
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
||
===Pharmacokinetics and Pharmacodynamics=== |
|||
| ⚫ | |||
*Rapidly concentrates in tissue, but poor concentration in urine and lung tissue |
|||
==Dosing== |
|||
*'''Intraabdominal infection:''' 100 mg IV load followed by 50 mg IV q12h |
|||
*'''Pneumonia:''' 100 mg IV load followed by 50 mg IV q12h |
|||
**High dosing may be useful in HAP/VAP with 100 mg IV q12h |
|||
*'''Skin and soft tissue infection:''' 100 mg IV load followed by 50 mg IV q12h |
|||
==Safety== |
|||
*Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP |
|||
*Commonly causes nausea, vomiting, and diarrhea |
|||
*Also anemia, thrombocytopenia, hepatitis, jaundice, AKI |
|||
| ⚫ | |||
Latest revision as of 12:56, 26 April 2021
Background
- Glycylcycline antibiotic
Spectrum of Activity
- Related to tetracycline and doxycycline, with expanded coverage to include streptococci and Enterobacteriaceae, but without coverage for unusual Gram-negative bacteria or Chlamydia trachomatis
- Does cover Acinetobacter and Stenotrophomonas
Pharmacokinetics and Pharmacodynamics
- Rapidly concentrates in tissue, but poor concentration in urine and lung tissue
Dosing
- Intraabdominal infection: 100 mg IV load followed by 50 mg IV q12h
- Pneumonia: 100 mg IV load followed by 50 mg IV q12h
- High dosing may be useful in HAP/VAP with 100 mg IV q12h
- Skin and soft tissue infection: 100 mg IV load followed by 50 mg IV q12h
Safety
- Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP
- Commonly causes nausea, vomiting, and diarrhea
- Also anemia, thrombocytopenia, hepatitis, jaundice, AKI
